Arbutus Biopharma Logo
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection SOUTH SAN FRANCISCO, Calif. and WARMINSTER, Pa., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that...
Arbutus Biopharma Logo
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
07 août 2020 07h30 HE | Arbutus Biopharma Corporation
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid...
Arbutus Biopharma Logo
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
05 août 2020 08h00 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Biopharma Logo
Arbutus to Report Second Quarter 2020 Financial Results
29 juil. 2020 08h00 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Biopharma Logo
Arbutus to Present at Jefferies Virtual Healthcare Conference
27 mai 2020 08h00 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic...
Arbutus Biopharma Logo
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
18 mai 2020 16h05 HE | Arbutus Biopharma Corporation
 Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 90 mg single-dose and 60 mg multi-dose cohorts initiated with data expected...
Arbutus Biopharma Logo
Arbutus to Present at UBS Virtual Global Healthcare Conference
12 mai 2020 08h00 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic...
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
11 mai 2020 06h00 HE | Arbutus Biopharma Corporation
Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa., May 11, 2020 (GLOBE NEWSWIRE) --...
Arbutus Biopharma Logo
Arbutus to Report First Quarter 2020 Financial Results
04 mai 2020 08h00 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 04, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its...
Arbutus Biopharma Logo
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
26 mars 2020 16h05 HE | Arbutus Biopharma Corporation
Positive single dose AB-729 data in chronic hepatitis B subjects supports further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional...